Achillion is a science-driven, patient-focused company leveraging its strengths across the continuum from discovery to commercialization to provide better treatments for people with serious diseases. We use a highly-disciplined, scientifically rigorous, patient-focused approach across the continuum from discovery to patient care to discover and develop innovative medicines. Our prolific and sustainable discovery engine for potent and specific small-molecule drug candidates has produced breakthroughs for chronic hepatitis C (HCV) infection and a novel platform for the treatment of complement-mediated diseases. We have generated three clinical-stage, oral HCV candidates and a proprietary library of greater than 1,000 small molecule factor D inhibitors. Achillion is rapidly becoming a fully-integrated commercial pharmaceutical company as it advances the complement platform and prepares to bring life saving medicines to patients with rare diseases.
Achillion Pharmaceuticals was founded in 1998 and is headquartered in New Haven, US